Staying well after depression (SWAD) CI Professor Mark Williams PI Professor Ian Russell Sholto Radford Research Officer

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

Depression Lawrence Pike.
Combining neuropsychology and genetics in the study of mood disorders Daniel Smith MRCPsych Division of Psychiatry, University of Edinburgh Specialist.
TalkingSpace & TalkingHealth The IAPT service, Oxfordshire and Buckinghamshire NHS Foundation Trust Christina Surawy: Oxford Mindfulness Centre, Oxford.
Improving Psychological Care After Stroke
Mindfulness-Based Cognitive Therapy : Implementation in the UK Health Service Rebecca Crane & Willem Kuyken Mindfulness Conference, Bangor University 9.
Preliminary Analyses of Recruiting Centre for Mindfulness Research and Practice Elaine Weatherley-Jones & Mariel Jones Presentation for the ‘Mindfulness.
Main Outcome Results November 6, 2009 Nancy J. Thompson, Ph.D., M.P.H.
Effectiveness of health checks to improve the physical health of patients with severe mental illness: a single blind cluster randomised controlled trial.
Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Referral Process: Referral options Referral form to be completed by members of treatment team. OR Self-referral & referral form signed by consultant Processing.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Mental Health from a Public Health Perspective Professor Carol S. Aneshensel Department of Community Health Sciences 10/12/09.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Behavioral Health Services for Injured or Ill workers – Collaborative Care Analysis and Recommendations January 22, 2015.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Describe and Evaluate the Cognitive Treatment for Schizophrenia
TREATING SPECIAL POPULATIONS. OVERVIEW Tobacco Treatment Smoking Outcomes Co-occurring Disorders Integration Tobacco Prevention.
COGNITIVE APPROACHES TO SUICIDE Center for Disease Control and Prevention February 6, 2004 Aaron T. Beck, M.D. Gregory K. Brown, Ph.D. University of Pennsylvania.
Mindfulness-based cognitive therapy for generalized anxiety disorder Susan Evans a,,, Stephen Ferrando a, Marianne Findler a, Charles Stowell a, Colette.
Mindfulness. Aims of this session Introduction to mindfulness How it helps depression and anxiety Relaxation exercise Research Questions Interactive.
Kate Comtois, PhD, MPH University of Washington Treatment Interventions for Suicide Prevention.
Click to edit Master subtitle style The Role of Attachment in brief group therapy for depression: An empirical study Dr Jo Wilson Professor Phil Richardson.
The European Network for Traumatic Stress Training & Practice
Dr. Thomas Richardson Clinical Psychologist (1,2) Dr. Lorraine Bell Consultant Clinical Psychologist (1) 1. Mental Health Recovery Teams, Solent NHS Trust,
Telephone-based coping skills training for patients awaiting lung transplantation The INSPIRE Investigators Duke University Medical Center, Durham, NC.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
Treatment for Adolescents With Depression Study (TADS)
SIGN Non-Pharmaceutical Management of Depression in Adults Recommendations.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
PROFESSOR RONA MOSS-MORRIS ADHERENCE TO PSYCHOLOGICAL INTERVENTIONS IN MS.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2012.
Non fatal deliberate self harm ( DSH) ‘A deliberate non-fatal act, whether physical, drug over dosage or poisoning, done in the knowledge that it was potentially.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Chapter 10: Depressive Disorders in Adolescents Megan Jeffreys V. Robin Weersing.
1 IRIS Initiative to Reduce the Impact of Schizophrenia DON’T DELAY! IT’S TIME TO REDUCE THE IMPACT OF PSYCHOSIS IN YOUNG PEOPLE……. NOW!
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Nancy J. Thompson, Ph.D., M.P.H., Archna Patel, M.P.H., Linda M. Selwa, M.D., Charles E. Begley, Ph.D., Robert T. Fraser, Ph.D., Erica Johnson, Ph.D.,
Mindfulness recent research. Summary Mindfulness –Why focus on depression MBCT –update of the trials ‘How does it work?’ Qualitative studies Mindfulness.
The expanding evidence for the efficacy of ACT: results from a meta analysis on clinical applications.
Depression Management Presentation 1 of 3 Documented diagnosis PHQ tool Depression care assessment.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Chapter 18 Bipolar Mood Disorder. Definition 1.Bipolar I disorder # disorder in which at least one manic or mixed episode has occurred # commonly accompanied.
PSYCHOTHERAPIES FOR BIPOLAR DISORDER Keith R Laws University of Hertfordshire
LO: To be able to describe and evaluate the Cognitive Treatment for Schizophrenia.
CNWL Talking Therapies Service Westminster Improving Access to Psychological Therapies.
Depression in children and young people referred to Specialist CAMHS: An audit of screening procedures. Dr. Michelle Rydon-Grange Clinical Psychologist,
Long-term effectiveness and cost- effectiveness of cognitive behavioural therapy for treatment resistant depression in primary care A follow-up of the.
NewAccess An innovative early intervention service for people with mild to moderate depression or anxiety.
Behavioural Activation for depression by the non specialist David Ekers Nurse Consultant Primary Care Mental Health Clinical Lead Durham and Darlington.
MBCT with TBI Groups A practitioner’s journey through training and practice with TBI patient groups Elly Nadorp, MSW.,RSW
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
PSY 436 Instructor: Emily Bullock Yowell, Ph.D.
3 July 2017 Working with students with Personality Disorder and Risk: Developing the Student Health Emotion Regulation Pathway (SHERPA) Dr Ian Barkataki.
The DEPression in Visual Impairment Trial:
Preventing relapse after depression: is MBCT the answer?
Qualitative Research Results Conclusions
Dr. Thomas Richardson Clinical Psychologist (1,2)
Behavioural Activation for Depression By the Non Specialist
Consultant Psychiatrist and Research Fellow, IoPPN.
The Mood Disorder Spectrum
PSY 436 Instructor: Emily E. Bullock, Ph.D.
Clinical Presentation
Describe and Evaluate the Cognitive Treatment for Schizophrenia
Addressing Crisis and Suicide Intervention
The Research Question Background: Question:
Depression Lawrence Pike.
Psychiatric comorbidities in adult survivors of major trauma:
Presentation transcript:

Staying well after depression (SWAD) CI Professor Mark Williams PI Professor Ian Russell Sholto Radford Research Officer

Depression a prevalent Condition Risk of recurrence 90% for individuals with 3 or more previous episodes. Suicide ideation is one of the most consistently recurring symptoms of depression. 80% of suicide would not occur without depression. Mindfulness-Based Cognitive Therapy (MBCT) is a promising approach to preventing relapse. Depression and suicide

MBCT for preventing relapse 3 centre study (Teasdale et al, 2000) Single centre replication study (Ma & Teasdale, 2004) Summary of results of both trials: MBCT approximately halved (70% to 39%) the likelihood of depressive relapse in patients who had had three of more episodes of depression MBCT now recommended by NICE as a treatment for prevention of depression.

MBCT vs Antidepressants (ADs) 123 patients with a history of recurrent depression MBCT (with or without ADs) was equal if not slightly better at preventing relapse than maintenance antidepressant treatment alone, and better at improving quality of life. MBCT is more expensive than maintenance ADs in first 12 mths; then MBCT becomes more cost effective (Kuyken et al 2008)

Research questions MBCT - effective relapse prevention of major depression and incidence of suicidal symptoms. Comparison with equally plausible treatment without meditation (CPE) “dismantling”. Understand potential moderators and mediators of treatment outcome.

Design Multi centre trial (Bangor Oxford) RCT – Participants randomised to three conditions:- Treatment as usual (TAU) Mindfulness-Based Cognitive Therapy (MBCT) + TAU Cognitive Psycho Education (CPE) + TAU Stratification - Centre, cohort, history of suicidality (none, ideation, attempt), antidepressants in past 7 days

Interventions Both 8 week courses, 2 hour sessions, 2 MBCT – manualised treatment combines training in mindfulness with cognitive therapy – 1 hour per day home practice (meditation + smaller tasks to cultivate mindfulness. CPE – Includes all elements of MBCT except experiential cultivation of mindfulness. Learn psychological process involved in relapse, mood monitoring, disengaging from unhelpful patterns of processing.

Assessment Assessment – treatment effects monitored Pre intervention T0, Post intervention T1, 3 months T2, six months T3, nine months T4, twelve months T5. Blind assessors – SCID + battery of questionnaires and cognitive tasks

Sample and recruitment Using 2:2:1 ratio – 5% significance level 300 participants 99% power for detection of difference CPE –MBCT with 20% attrition 375 target. Referral – advertisements in community, clinics + GP surgeries, referral from GP’s and mental health clinicians, talks a t professional meetings. Preliminary phone screening - recruiters Detailed assessment (SCID) - assessors

Inclusion criteriaExclusion criteria Age History of, schizophrenia, Schizoaffective disorder, Bipolar 1, current severe substance abuse, primary diagnosis of OCD or eating disorder, regular self harm. DSM-IV criteria major depression >3 episodes (2 in past 5 years 1 in past 2 years Positive continuing response to CBT NIMH guidelines for recovery (1 week in past 8 of core symptom or suicidal feelings + 1 other symptom. Psychotherapy of counselling more than once per month. Giving informed consent + Consent from GP Cannot complete baseline assessment

Participants randomised n = 274 did not attend at least one follow up n =19 VariableBreakdown GenderFemale =198 (72%) Male =76 (28%) Age FemaleMean = Minimum = 18 Maximum = 68 Age MaleMean = Minimum = 18 Maximum 66 Antidepressants used at baseline No = 154 (56%) Yes 120 ( 44%) Suicidality – historyNone = 53 (20%) Ideation =138 (50%) Attempt =83 (30%) Number of previous episodes MDD (n= 240) Mean = 7 Minimum = 3 Maximum =45

Analysis Intention to treat analysis (ITT) Primary outcome – time to relapse or recurrence of MDD in weeks. Continuous quantitative measure of outcome also used (HRSD) for severity and to strengthen the dichotomised outcome. Other quantitative measures used include BDI-II, BHS,BSS, EQ5D. Secondary outcome- recurrence of suicidal ideation. Firstly - in participants who relapse Secondly - severity of suicidal symptoms for all participants Beck scale for suicide ideation (BSS) + MINNI suicide-tracking measure Thirdly – suicidal cognitions between groups with AnCova. T1 and T5 with T0 as covariate

Mediation Assessing cognitive measures Mindfulness, suppression, self compassion, rumination, autobiographical memory and executive capacity Regression on both the dichotomous outcome (binary logisitc) of relapse and on worst HRSD score (linear) during follow up.

Summary Recurrent depression is common and serious particularly for those who become suicidal when depressed. Urgent need to develop treatments that produce sustainable reductions in risk of recurrence And to identify the critical therapeutic factors to refine the approach for the future